Pancreatic Cancer Research

ResearcherTel Aviv UniversityNo recent work listed

Ben Boursi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1304-8340; OpenAlex author ID A5046961512. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper

Papers 11

  1. Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival. Co-author DOI 10.1001/jamanetworkopen.2023.45013↗
  2. Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes. Co-author DOI 10.1016/j.cgh.2021.10.037↗
  3. A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes. Co-author DOI 10.1097/meg.0000000000002052↗
  4. Validation of the Enriching New-Onset Diabetes for Pancreatic Cancer Model: A Retrospective Cohort Study Using Real-World Data. Co-author DOI 10.1097/mpa.0000000000002000↗
  5. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Pha… Co-author DOI 10.1001/jamaoncol.2021.0006↗
  6. Digoxin use is associated with pancreatic cancer risk but does not affect survival. Co-author DOI 10.1007/s10552-020-01352-7↗
  7. Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. Last author DOI 10.1002/pds.4993↗
  8. Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/jop.19.00328↗
  9. Total Serum Cholesterol and Pancreatic Cancer: A Nested Case-Control Study. First author DOI 10.1158/1055-9965.epi-18-0421↗
  10. Proton pump inhibitors on pancreatic cancer risk and survival. First author DOI 10.1016/j.canep.2016.12.006↗
  11. A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Co-author DOI 10.1053/j.gastro.2016.11.046↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yu‐Xiao Yang · 8 shared papers, 2017–2022 · strength 1.11
  2. Ronac Mamtani · 7 shared papers, 2017–2023 · strength 0.95
  3. Kim A. Reiss · 4 shared papers, 2020–2023 · strength 0.58
  4. Talia Golan · 3 shared papers, 2020–2023 · strength 0.42
  5. Andrew D. Rhim · 2 shared papers, 2017–2022 · strength 0.24
  6. Susan M. Domchek · 1 shared paper, 2023 · strength 0.20
  7. Gabriel Chodick · 1 shared paper, 2022 · strength 0.17
  8. Louise L. Wang · 1 shared paper, 2022 · strength 0.17
  9. William Chang-Yuen Chen · 1 shared paper, 2019 · strength 0.14
  10. Milind M. Javle · 1 shared paper, 2021 · strength 0.12
  11. Gauri A Varadhachary · 1 shared paper, 2021 · strength 0.12
  12. Robert A. Wolff · 1 shared paper, 2021 · strength 0.12
  13. David R. Fogelman · 1 shared paper, 2021 · strength 0.12
  14. Malcolm D. Kearns · 1 shared paper, 2017 · strength 0.12
  15. Erin Mary Bange · 1 shared paper, 2020 · strength 0.11
  16. Jeffrey D. Goldstein · 1 shared paper, 2020 · strength 0.09
  17. Akram Saad · 1 shared paper, 2020 · strength 0.09
  18. Yaacov Richard Lawrence · 1 shared paper, 2020 · strength 0.09
  19. Anil K. Rustgi · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.